Dennis Ding
Stock Analyst at Jefferies
(2.01)
# 3,100
Out of 5,113 analysts
15
Total ratings
40%
Success rate
8.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.28 | +1.54% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $21.91 | -8.72% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $32.34 | -19.60% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $51.32 | +7.17% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.59 | +403.14% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $26.42 | +32.48% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.14 | +69.08% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.47 | +34.23% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $2.05 | +1,119.51% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $45.85 | -52.02% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $31.88 | -24.72% | 1 | Dec 19, 2022 |
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.28
Upside: +1.54%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $21.91
Upside: -8.72%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $32.34
Upside: -19.60%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $51.32
Upside: +7.17%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $26.42
Upside: +32.48%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.14
Upside: +69.08%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.47
Upside: +34.23%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $2.05
Upside: +1,119.51%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $45.85
Upside: -52.02%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $31.88
Upside: -24.72%